Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pacific Edge Limited ( (PFGTF) ) has shared an announcement.
Pacific Edge Limited is undertaking a capital raising initiative through the issuance of new fully paid ordinary shares, aiming to raise approximately NZ$16 million via a non-underwritten placement and up to NZ$5 million through a retail offer structured as a share purchase plan. This move, which includes a proposal to increase director remuneration through share issuance, is not expected to affect the control of the company and aligns with regulatory compliance, potentially strengthening its financial position and operational capabilities.
More about Pacific Edge Limited
Pacific Edge Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic tests for the early detection and management of cancer. The company is listed on both the NZX and ASX, indicating its market focus in New Zealand and Australia.
For a thorough assessment of PFGTF stock, go to TipRanks’ Stock Analysis page.